Close

BIO Applauds FDA Action on AquAdvantage® Salmon

Mar 8 2019
The Biotechnology Innovation Organization (BIO) released the following statement on the action taken today by the U.S. Food & Drug Administration (FDA) which will allow AquaBounty Technologies, an American company, to commercialize its genetically engineered AquAdvantage® Salmon in the U.S. market.

BIO Applauds Multi-Agency Framework for Advancing the Bioeconomy

Mar 5 2019
The Biotechnology Innovation Organization (BIO) today released the following statement in response to the release of The Bioeconomy Initiative: Implementation Framework, a multi-agency strategy aimed at accelerating innovative technologies that harness the nation’s biomass resources for affordable biofuels, bioproducts, and biopower:

BIO Statement on Ambassador Lighthizer and Secretary Perdue Testimonies

Feb 27 2019
BIO President and CEO Jim Greenwood released the following statement on U.S. Trade Representative Robert Lighthizer’s testimony at a House Ways and Means Committee hearing on the U.S.-China trade deal and U.S. Secretary of Agriculture Sonny Perdue’s testimony at a House Agriculture Committee hearing on the state of the rural economy.  

BIO Announces Partnership with Taiwan BIO for 2019 Conference and Exhibition

Feb 20 2019
The Biotechnology Innovation Organization (BIO) announced today it will join the Taiwan Bio-Industry Organization (Taiwan BIO) to host BIO Asia-Taiwan from July 24-28 in Taipei, Taiwan. 

BIO Statement on CMS Proposed Decision Memo for the CAR-T National Coverage Determination

Feb 15 2019
BIO Executive Vice President for Health Policy Dan Durham issued the following statement regarding the CMS proposed decision memo for the CAR-T National Coverage Determination.

BIO Applauds Sens. Tillis, Sinema, Peters, and Perdue for Introducing the Fostering Innovation Act

Feb 13 2019
The Biotechnology Innovation Organization (BIO) applauds Sens. Thom Tillis (R-NC), Kyrsten Sinema (D-AZ), Gary Peters (D-MI), and David Perdue (R-GA) for introducing the Fostering Innovation Act (S.452) to build on the success of the Jumpstart Our Business Startups (JOBS) Act. 

BIO Announces Brent Erickson to Step Down as Executive Vice President, Industrial and Environmental Section

Feb 11 2019
The Biotechnology Innovation Organization (BIO) announced today that after 19 years leading the Industrial and Environmental Section, Executive Vice President Brent Erickson will step down from the organization in March 2019 to begin new business ventures. 

New Report Demonstrates High Costs and Low Benefits of Sarbanes-Oxley 404(b) Compliance for Emerging Biotechs

Feb 11 2019
To recognize National Inventors’ Day, the Biotechnology Innovation Organization (BIO) released a new report, “Science or Compliance: Will Section 404(b) Compliance Impede Innovation by Emerging Growth Companies in the Biotech Industry?” The report shows the detrimental impact of Sarbanes-Oxley 404(b) on biopharmaceutical emerging growth companies (Bio-EGCs) and demonstrates how this regulatory requirement harms innovation and capital formation without any corresponding investor benefit. 

BIO Encouraged by Improved U.S. Ranking in Global Index of Patent System Strength

Feb 7 2019
But New Legislative Proposals Endanger Progress

BIO Statement on Hatch-Waxman Integrity Act of 2019

Feb 7 2019
BIO applauds the leadership of Senator Thom Tillis (R- NC) and Congressman Bill Flores (R-17 TX) for introducing the “Hatch-Waxman Integrity Act of 2019” to preserve the time-tested approach of the HWA while strengthening the ability of patent owners to fairly defend against abusive efforts to invalidate patents for innovative life-saving medical therapies.